Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06397651 | A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life | active not recruiting | N/A | 146 | Complement Theory Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02755896 | Trial to Compare Radiation Fibrosis With Five Versus Three Fractions | active not recruiting | Phase 2 | 350 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 15, 2025 |
| clinicaltrials |
| NCT04745754 | The Engaging Primary Care in Cancer Survivorship (EPICS) Study(EPICS) | active not recruiting | N/A | 2,450 | Kaiser PermanenteOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04379414 | YES Study - Newly Diagnosed/Metastatic Intervention(YES) | active not recruiting | N/A | 400 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT04661982 | Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer | active not recruiting | — | 500 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer(WIN-B) | active not recruiting | Phase 1 / Phase 2 | 76 | MedSIROTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04438681 | Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients(INSTIGO) | active not recruiting | — | 90 | Centre Jean PerrinOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05410951 | LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients(LobularCard) | active not recruiting | — | 800 | European Institute of OncologyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer(Triple-B) | active not recruiting | Phase 2 | 304 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03143322 | Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases(STEREO-OS) | active not recruiting | N/A | 168 | UNICANCEROTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04193059 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer(PANSY) | active not recruiting | Phase 3 | 1,560 | Fudan UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06495164 | A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer | active not recruiting | — | 1 | PfizerINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01516190 | The Preoperative Health & Body Study(PreHab) | active not recruiting | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03657628 | Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue | active not recruiting | N/A | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05266105 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | active not recruiting | Phase 1 | 60 | Olema Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06572774 | Community Clinic Model to Improve Early Detection of Breast and Cervical Cancers in Kenya(C3Link) | active not recruiting | N/A | 5,400 | ImplenomicsOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04514419 | Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | active not recruiting | Phase 3 | 408 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03731845 | Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer(ESIGON) | active not recruiting | N/A | 73 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05889988 | A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients | active not recruiting | — | 36 | Mayo ClinicOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04565054 | Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC(ADAPTlate) | active not recruiting | Phase 3 | 1,260 | Women's Cancer Study Group GmbHOTHER | 3 | Nov 19, 2025 | clinicaltrials |
| NCT06328738 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | active not recruiting | Phase 1 | 275 | Enliven TherapeuticsINDUSTRY | 7 | Nov 19, 2025 | clinicaltrials |
| NCT04042701 | DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 115 | Daiichi SankyoINDUSTRY | 4 | Nov 18, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT06735742 | A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer | active not recruiting | — | 3 | PfizerINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT01093612 | Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer | active not recruiting | N/A | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02827877 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | active not recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05949021 | OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Mridula George, MDOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05912231 | Ultrahypofractionation and Normal Tissue Toxicity | active not recruiting | N/A | 60 | Massachusetts General HospitalOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT01153035 | Excision Followed by Radiofrequency Ablation for Breast Cancer(ABLATE) | active not recruiting | N/A | 104 | University of ArkansasOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT01230346 | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | active not recruiting | N/A | 493 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT01472094 | The Hurria Older PatiEnts (HOPE) With Breast Cancer Study | active not recruiting | — | 700 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT00572481 | Axillary Reverse Mapping(ARM) | active not recruiting | Phase 2 | 1,000 | University of ArkansasOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT02603341 | Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial | active not recruiting | N/A | 1,238 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05078190 | Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer(CCT2) | active not recruiting | — | 200 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT00996710 | Genomic Structural Variation in Cancer Susceptibility | active not recruiting | — | 1,275 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03707340 | A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04821141 | Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens | active not recruiting | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | active not recruiting | Phase 1 | 145 | NanobiotixINDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT06260332 | Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors | active not recruiting | N/A | 25 | New Mexico Cancer Research AllianceOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03292198 | Subclinical Lymphedema Treatment Study(SLT) | active not recruiting | N/A | 267 | Mercy ResearchOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04272801 | Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer(POWER) | active not recruiting | Phase 2 | 84 | Shayna Showalter, MDOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer(MONARCH 2) | active not recruiting | Phase 3 | 669 | Eli Lilly and CompanyINDUSTRY | 20 | Oct 21, 2025 | clinicaltrials |
| NCT03529110 | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | active not recruiting | Phase 3 | 524 | Daiichi SankyoINDUSTRY | 15 | Oct 21, 2025 | clinicaltrials |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | active not recruiting | Phase 3 | 228 | DualityBio Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2025source: clinicaltrials